Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for chronic weight management) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist
(2025, January 15)
Visible changes in body composition, skin texture, and muscle recovery typically manifest after 3 to 6 months of consistent treatment under medical supervision
L-theanine : An amino acid found in tea leaves, L-theanine is often taken to promote relaxation and improve sleep quality
Finally, lifestyle and support are integral to the success of GLP-1 treatment
Key mechanisms: Directly inhibits NF-B the central transcription factor governing the body's inflammatory cascade Suppresses MAP kinase signalling pathways Reduces pro-inflammatory cytokines including TNF-, IL-1, and IL-6 Acts via PepT1 transporters in intestinal epithelial and immune cells, targeting gut-resident inflammation at the tissue level The evidence: A landmark study published in Gastroenterology demonstrated that nanomolar concentrations of KPV inhibit NF-B and MAP kinase inflammatory pathways and reduce pro-inflammatory cytokine secretion and that oral administration of KPV reduces the incidence of chemically induced colitis in mice as measured by both histology and cytokine expression
